Obesity and arterial hypertension

Česká verzia

Authors: Ľ. Gašpar ¹; P. Poliak ²; M. Makovník ¹; S. Hlinšťáková ¹; B. Krahulec ¹; T. Pišková ¹; M. Bendžala ¹
Authors place of work: II. interná klinika Lekárskej fakulty UK a FNsP Bratislava, Slovenská republika, prednosta prof. MU Dr. Andrej Dukát, CSc., FESC ¹; I. anestéziologicko‑resuscitačná klinika Lekárskej fakulty UK a FNsP Bratislava, Slovenská republika, prednosta MU Dr. Juraj Koutun, CSc. ²
Published in the journal: Vnitř Lék 2010; 56(10): 1074-1077
Category: Obesity 2010

Summary

Obesity is an independent risk factor for the development and progression of hypertension, cardiovascular disease and chronic kidney disease. There is growing evidence that obesity and associated metabolic abnormalities may induce and accelerate renal complications in essential hypertension. The clustering of obesity and other features of the metabolic syndrome might have important implications for prevention, particularly with regard to whether interventions targeted at visceral obesity would have beneficial effects on cardiovascular and renal morbidity.

Key words:
obesity – arterial hypertension – metabolic syndrome – pathophysiological relationship

Zdroje

1. Branca F, Nikogosian H, Lobstein T. The Challenge of Obesity in the WHO European Region and the Strategies for Response. World Health Organisation 2007. Available from: http:/ / www.euro.who.int/ document/ E90711.pdf.

2. Haslam DW, James WP. Obesity. Lancet 2005; 366: 1197– 1209.

3. Narkiewicz K. Obesity and hypertension – the issue is more complex than we thought. Nephrol Dial Transplant 2006; 21: 264– 267.

4. Bonora E. The metabolic syndrome and cardiovascular disease. Ann Med 2006; 38: 64– 80.

5. Foley RN, Wang C, Collins AJ. Cardiovascular risk factor profile and kidney function stage in the US general population: the NHANES III study. Mayo Clin Proc 2005; 80: 1270– 1277.

6. Kastarinen MJ, Nissinen AM, Vartiainen EA et al. Blood pressure levels and obesity trends in hypertensive and normotensive Finnish population from 1982 to 1997. J Hypertens 2000; 18: 253– 262.

7. Krauss RM, Winston M, Fletcher RN et al. Obesity: impact on cardiovascular disease. Circulation 1998; 98: 1472– 1476.

8. Messerli FH, Christie B, DeCarvalho H et al. Obesity and essential hypertension: hemodynamics, intravascular volume, sodium excretion, and plasma renin activity. Arch Intern Med 1981; 141: 81– 85.

9. Kurtz TW, Klein U. Next generation multifunctional angiotensin receptor blockers. Hypertens Res 2009; 32: 826– 834.

10. Jern S, Bergbrant JS, Bjöntorp K et al. Relation of central hemodynamics to obesity and body fat distribution. Hypertension 1992; 19: 520– 527.

11. Howell SJ, Sear JW, Foëx P. Hypertension, hypertensive heart disease and perioperative cardiac risk. Br J Anaesth 2004; 92: 570– 583.

12. Rahmouni K, Correia M, Haynes WG et al. Obesity‑associated hypertension: new insights into mechanisms. Hypertension 2005; 45: 9– 14.

13. Redon J, Cifkova R, Laurent S et al. The metabolic syndrome in hypertension: European society of hypertension position statement. J Hypertens 2008; 26: 1891– 1900.

14. Goodfriend TL, Calhoun DA. Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy. Hypertension 2004; 43: 518– 524.

15. Goodfriend TL, Ball DL, Egan BM et al. Epoxy‑ keto derivate of linoleic acid stimulates aldosterone secretion. Hypertension 2004; 43: 358– 363.

16. Carlyle M, Jones OB, Kuo JJ et al. Chronic cardiovascular and renal actions of leptin: role of adrenergic activity. Hypertension 2002; 39: 496– 501.

17. Marsh A, Fontes M, Killinger S et al. Cardiovascular responses evoked by leptin acting on neurons in the ventromedial and dorsomedial hypothalamus. Hypertension 2003; 42: 488– 493.

18. da Silva AA, Kuo JJ, Hall JE. Role of hypothalamic melanocortin 3/ 4- receptors in mediating chronic cardiovascular, renal, and metabolic actions of leptin. Hypertension 2004; 43: 1312– 1317.

19. Fábryová Ľ. Vzťah viscerálnej obezity ku kardiometabolickým faktorom. Via pract 2008; 5: 122– 125.

20. Cardillo C, Campia U, Iantorno M et al. Enhanced vascular activity of endogenous endothelin‑1 in obese hypertensive patients. Hypertension 2004; 43: 36– 40.

21. Beltowski J, Wójcicka G, Marciniak A et al. Oxidative stress, nitric oxide production and renal sodium handling in leptin‑induced hypertension. Life Sci 2004; 74: 2987– 3000.

22. Kambham N, Markowitz GS, Valeri AM et al. Obesity‑related glomerulopathy: an emerging epidemic. Kidney Int 2001; 59: 1498– 1509.

23. Keller G, Zimmer G, Mall G et al. Nephron number in patients with primary hypertension. N Engl J Med 2003; 348: 101– 108.

24. Praga M, Hernández E, Herrero JC et al. Influence of obesity on the appearence of proteinuria and renal insufficiency after unilateral nephrectomy. Kidney Int 2000; 58: 2111– 2118.

25. Sin DD, Man SF. Impaired lung function and serum leptin in men and women with normal body weight: a population based study. Thorax 2003; 58: 695– 698.

26. Schünemann HJ, Dorn J, Grant BJ et al. Pulmonary function is a long‑term predictor of mortality in the general population: 29‑year follow‑up of the Buffalo Health Study. Chest 2000; 118: 656– 664.

27. Nowbar S, Burkart KM, Gonzales R et al. Obesity‑associated hypoventilation in hospitalized patients: prevalence, effects, and outcome. Am J Med 2004; 116: 1– 7.

28. Šimková I et al. Pľúcna hypertenzia očami kardiológa. Bratislala: SAP 2009.

29. Julius S, Valentini M, Palatini P. Overweight and hypertension: a 2- way street? Hypertension 2000; 35: 807– 813.

30. Flegal KM, Graubard BI, Williamson DF et al. Cause‑ specific excess deaths associated with underweight, overweight, and obesity. JAMA 2007; 298: 2028– 2037.

31. Svačina Š. Obezita a psychofarmaka. Praha: Triton 2002.